Prophylactic and Therapeutic Breast Conservation in BRCA1/2 Mutation Carriers

• Main Authors: Randal L. Croshaw, Megan L. Marshall, Tesha L. Williams, Kathleen M. Erb, Thomas B. Julian
• Format: Article
• Language: English
• Published: Hindawi Limited 2011-01-01
• Series: International Journal of Breast Cancer
• Online Access: http://dx.doi.org/10.4061/2011/481563

Breast-conserving therapy (BCT) for sporadic breast cancer has been widely accepted by surgeons and patients alike. While BCT is associated with a higher risk of ipsilateral breast tumor recurrence (IBTR), it has not been shown to decrease overall survival (OS) in comparison with mastectomy. Many women with a BRCA1/2 mutation opt for mastectomy instead of breast-conserving measures at the time of a breast cancer diagnosis. In some cases, this is due to fear of aggressive disease, but to date, there have been no studies offering strong evidence that breast conservation should not be offered to these women. BRCA1/2-associated breast cancer has not been found to be more aggressive or resistant to treatment than comparable sporadic tumors, and no study has shown an actual survival advantage for mastectomy in appropriately treated affected mutation carriers. This paper reviews the available literature for breast conservation and surgical decision making in BRCA1/2 mutation carriers.